PubMed COVID-19 Clinical Care

No abstract

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via

Alongside vaccines, antiviral drugs are becoming an integral part of our response to the SARS-CoV-2 pandemic. Nirmatrelvir-an orally available inhibitor of the 3-chymotrypsin-like cysteine protease-has been shown to reduce the risk of progression to

Background This study aims to provide a better knowledge of COVID-19 that will aid in the formulation of future health policy by detailing the pathophysiology, case detection, and treatment, as well as management and prevention activities

CONCLUSION: The risk factors, identified in this study, can be used as significant independent predictors for developing MS post-COVID-19 vaccinations.

COVID-19 in the pediatric population is mostly asymptomatic. However, 1 out of 5 children presents non-specific neurologic symptoms such as headache, weakness, or myalgia. Furthermore, rarer forms of neurological diseases are increasingly being

5-Methylcytosine (m⁵C) is a widespread post-transcriptional RNA modification and is reported to be involved in manifold cellular responses and biological processes through regulating RNA metabolism. However, its regulatory role in antiviral innate

CONCLUSIONS: We report a case of nonepisodic AE after COVID-19 vaccination that was successfully treated with reslizumab.

To evaluate the effect of Nirmatrelvir-ritonavir therapy and COVID-19 vaccination on clinical outcomes of SARS-Cov-2 Omicron infection，we retrospectively analyzed the clinical data of 762 adult patients with confirmed Omicron BA2.2 variant infection

CONCLUSION: NEAE can develop after COVID-19 and should be considered in the differential diagnosis of non-pitting oedema of the extremities.